1.散发性胰岛素瘤中MLH1、MSH2失活导致微卫星不稳定及其临床意义 2.α-internexin在胰腺内分泌肿瘤中的异常表达及其临床意义
|
摘要
第一部分散发性胰岛素瘤中错配修复基因MLH1、MSH2失活导致微卫星不稳定及其临床意义
研究目的散发性胰岛素瘤的分子发病机制未明。目前仍缺乏可靠的用于鉴别胰岛素瘤良恶性的分子标志物。本课题第一部分的研究目的是明确胰岛素瘤是否发生错配修复基因失活,从而导致微卫星不稳定;错配修复基因的异常以及微卫星不稳定是否可用于鉴别该类肿瘤的良恶性和判断预后。
实验方法用PCR方法检测61例胰岛素瘤的微卫星不稳定,MLH1基因的杂合缺失和启动子甲基化。用变性高效液相色谱分析方法测定外显子突变并DNA测序验证。用免疫组织化学染色方法检测MLH1和MSH2蛋白在肿瘤及瘤旁组织中的表达。分别用单因素和多因素分析方法对实验数据与患者的临床病理学资料进行相关性分析。
实验结果在58个散发性胰岛素瘤中,MLH1和MSH2蛋白表达下降分别为38%和16%。散发性胰岛素瘤发生MLH1基因启动子高甲基化和基因杂合缺失分别为32%和50%。MLH1基因启动子高甲基化或同时发生启动子高甲基化和基因杂合缺失与蛋白的表达下降显著相关(P值分别为0.041和0.027)。散发性胰岛素瘤中未发现MSH2基因杂合缺失。1/3的散发性胰岛素瘤发生高频的微卫星不稳定,MLH1或MSH2蛋白表达下降与高频的微卫星不稳定显著相关(P=0.006和0.049)。MLH1和MSH2蛋白表达同时下降也与高频的微卫星不稳定显著相关(P=0.004)。
与临床病理相关分析显示,高频的微卫星不稳定、MLH1蛋白表达下降或MLH1和MSH2蛋白表达同时下降与肿瘤良恶性显著相关(P值分别为2.6×10~(-5)、0.008和0.018)。高频的微卫星不稳定、MLH1蛋白表达下降以及同时发生MLH1和MSH2蛋白表达下降均为患者未即时治愈的独立影响因素(P值分别为0.002、0.011和0.030)。
实验结论在散发性胰岛素瘤中MLH1基因的失活与杂合缺失和基因启动子高甲基化有关。MLH1和MSH2基因的表达下降以及高频的微卫星不稳定可作为鉴别胰岛素瘤的良恶性以及辅助判断患者的预后的分子标志物。错配修复基因的异常可能在胰岛素瘤的发生中起一定的作用。
第二部分α-internexin在胰腺内分泌肿瘤中的异常表达及其临床意义
研究目的胰腺内分泌肿瘤的分子发病机制未明。目前仍缺乏可靠的用于鉴别胰腺内分泌肿瘤良恶性的分子标志物。课题第二部分的研究目的是明确胰腺内分泌肿瘤是否存在α-internexin的表达及其表达调控机制;探讨α-internexin的表达是否可作为分子标志物用于鉴别该类肿瘤的良恶性和判断预后。
实验方法用免疫组织化学染色方法检测242例胰腺内分泌肿瘤α-internexin的表达,其中部分标本用免疫印迹法及反转录PCR法检测α-internexin蛋白及mRNA的表达进行确认。免疫印迹法检测17株细胞系该蛋白的表达。分别用反转录PCR、DNA测序和染色质免疫沉淀检测5-aza-dC作用前后人肿瘤细胞系α-internexin的mRNA表达、启动子甲基化及组蛋白修饰状态。分别用单因素和多因素分析方法对实验数据与临床病理学资料进行相关性统计分析,Kaplan-Meier法用于生存分析。
实验结果238个胰腺内分泌肿瘤中有132个肿瘤(55.4%)表达α-internexin蛋白,而对照组53个胰腺组织标本中仅1个标本(2%)表达该蛋白(P=9.97×10~(-14))。α-internexin的表达率在功能性与无功能性胰腺内分泌肿瘤之间有很显著地差异(71.4%vs.35.4%,P=2.36×10~(-8))。在恶性肿瘤、发生转移的肿瘤中α-internexin蛋白表达明显下降(P值分别为0.016、0.003)。α-internexin蛋白表达下降与患者因肿瘤死亡或肿瘤未治愈的不良预后均显著相关(P值分别为0.025或0.017)。
在多种人肿瘤细胞系中,α-internexin蛋白表达下降与其启动子甲基化显著相关(P=0.002)。但在正常胰腺和胰腺内分泌肿瘤的组织中发现α-internexin基因的启动子处于非甲基化状态,提示该基因在胰腺内分泌肿瘤中的表达调控与启动子甲基化与否无明显相关。
实验结论α-internexin表达下降可作为鉴别胰腺内分泌肿瘤的良恶性以及辅助判断患者的预后的分子标志物。α-internexin启动子甲基化是多种肿瘤细胞系中调控α-internexin蛋白表达的重要机制,但与胰腺内分泌肿瘤中α-internexin蛋白的表达无明显相关。
Purpose The molecular pathogenesis of sporadic insulinomas is unknown.There is a lack of biomarker to distinguish benign and malignant insulinoma.The aim of the first part of this study is to identify if mismatch repair genes are inactivated in insulinomas,which induce the microsatellite instability, and if the genetic/epigenetic alterations of the gene(s) as well as microsatellite instability could be used to distinguish benign and malignant insulinoma and to predict the outcome of the patients.
Experimental Design We detected microsatellite instability,allelic typing and promoter methylation by PCR.Denaturing high performance liquid chromatography(DHPLC) was used to analyze exon mutations which were further confirmed by sequencing.Expression of MLH1 and MSH2 gene in 61 insulinomas and paired normal tissues were tested by immunohistochemical staining.The data were correlated with clinical-pathological characteristics,and were analyzed by both univariate and multivariate statistical methods.
Results We found expression of MLH1 and MSH2 protein was reduced in 38%and 16%of 58 sporadic insulinomas,respectively.Promoter methylation and loss of heterozygosity(LOH) of MLH1 gene was found in 32% and 50%of sporadic insulinomas,respectively.Promoter methylation or both methylation and LOH of MLH1 were significantly associated with reduced expression of MLH1(P=0.041 and P=0.027,respectively).LOH of MSH2 gene was not found in sporadic insulinomas.A high rate of microsatellite instability (MSI-H) was found in 33%of sporadic insulinomas,which was correlated with the reduction of MLH1 or MSH2(P=0.006 and P=0.049,respectively).Reduced expression of both MLH1 and MSH2 were significantly correlated with MSI-H (P=0.004).Reduced expression of MLH1 or both MLH1 and MSH2 were significantly associated with tumor malignancy(P=0.008 or P=0.018).Although the rate of reduced expression of MSH2 in malignant tumors was higher than in benign tumors,the statistic difference was not significant(P=0.072).MSI-H was significantly associated with tumor malignancy and incurable insulinoma(P=2.6×10~(-5) and P=0.002,respectively).
Conclusion Allelic loss and promoter methylation contribute to the inactivation of MLH1 gene in sporadic insulinomas.Assessing alterations of MLH1 and MSH2 gene,as well as MSI-H,could be used to distinguish benign from malignant insulinomas and to predict the outcome of patients.The genetic/epigenetic silencing of MLH1 gene may play an important role in tumorigenesis in a subset of the tumors.
Purpose The molecular pathogenesis of pancreatic endocrine tumors is unknown.There is a lack of biomarker to distinguish benign and malignant pancreatic endocrine tumors.The aim of the second part of this study is to identify ifα-internexin expressed in pancreatic endocrine tumors,as well as analyzing the molecular mechanisms regulating the expression ofα-internexin; and to find if the alteration of the expression ofα-internexin could be used to distinguish benign and malignant pancreatic endocrine tumors and to predict the outcome of the patients.
Experimental Design Expression ofα-internexin in 242 pancreatic endocrine tumors were tested by immunohistochemical staining,and part of the tumors were also tested the expression of mRNA and protein ofα-internexin by RT-PCR and western blot,respectively.We also detected the protein expression ofα-internexin in 17 cell lines by western blot.Before and after treated with 5-aza-dC,the mRNA,promoter methylation and histon modification ofα-internexin in cell lines were detected by RT-PCR,sequencing and chromatin immunoprecipitation analysis,respectively.The data were correlated with clinical-pathological characteristics,and were analyzed by both univariate and multivariate statistical methods.Kaplan-Meier was used to analyse the cumulative survival.
Results We found 132 of 238(55.4%) pancreatic endocrine tumors expressedα-internexin,whereas only one of 53 pancreatic tissues expressed the protein(P = 9.97×10~(-14)).The percentage of the expression ofα-internexin was significantly higher in functional tumors than in non-functional ones(71.4%vs. 35.4%,P = 2.36×10~(-8)).Reduced expression ofα-internexin was significantly correlated with malignant tumors or tumors with metastasis(P=0.016 and P=0.003,respectively).Besides,reduced expression ofα-internexin was also significantly correlated with patients' outcome of dead with tumors or survival with tumors(P=0.025 and P=0.017,respectively).
Promoter methylation was significantly associated with reduced expression ofα-internexin in 14 tumor cell lines(P=0.002).However,promoter unmethylation status was found in both pancreatic endocrine tumors and normal pancreatic tissues,which indicated that promoter methylation was not play a role in the regulation mechanism of the expression ofα-internexin in pancreatic endocrine tumors.
Conclusion Reduced expression ofα-internexin could be used to distinguish benign from malignant pancreatic endocrine tumors and to predict the outcome of patients.Promoter methylation contributes to the inactivation ofα-internexin gene in many kinds of tumor cell lines,but it may not play an important role in pancreatic endocrine tumors.
研究目的散发性胰岛素瘤的分子发病机制未明。目前仍缺乏可靠的用于鉴别胰岛素瘤良恶性的分子标志物。本课题第一部分的研究目的是明确胰岛素瘤是否发生错配修复基因失活,从而导致微卫星不稳定;错配修复基因的异常以及微卫星不稳定是否可用于鉴别该类肿瘤的良恶性和判断预后。
实验方法用PCR方法检测61例胰岛素瘤的微卫星不稳定,MLH1基因的杂合缺失和启动子甲基化。用变性高效液相色谱分析方法测定外显子突变并DNA测序验证。用免疫组织化学染色方法检测MLH1和MSH2蛋白在肿瘤及瘤旁组织中的表达。分别用单因素和多因素分析方法对实验数据与患者的临床病理学资料进行相关性分析。
实验结果在58个散发性胰岛素瘤中,MLH1和MSH2蛋白表达下降分别为38%和16%。散发性胰岛素瘤发生MLH1基因启动子高甲基化和基因杂合缺失分别为32%和50%。MLH1基因启动子高甲基化或同时发生启动子高甲基化和基因杂合缺失与蛋白的表达下降显著相关(P值分别为0.041和0.027)。散发性胰岛素瘤中未发现MSH2基因杂合缺失。1/3的散发性胰岛素瘤发生高频的微卫星不稳定,MLH1或MSH2蛋白表达下降与高频的微卫星不稳定显著相关(P=0.006和0.049)。MLH1和MSH2蛋白表达同时下降也与高频的微卫星不稳定显著相关(P=0.004)。
与临床病理相关分析显示,高频的微卫星不稳定、MLH1蛋白表达下降或MLH1和MSH2蛋白表达同时下降与肿瘤良恶性显著相关(P值分别为2.6×10~(-5)、0.008和0.018)。高频的微卫星不稳定、MLH1蛋白表达下降以及同时发生MLH1和MSH2蛋白表达下降均为患者未即时治愈的独立影响因素(P值分别为0.002、0.011和0.030)。
实验结论在散发性胰岛素瘤中MLH1基因的失活与杂合缺失和基因启动子高甲基化有关。MLH1和MSH2基因的表达下降以及高频的微卫星不稳定可作为鉴别胰岛素瘤的良恶性以及辅助判断患者的预后的分子标志物。错配修复基因的异常可能在胰岛素瘤的发生中起一定的作用。
第二部分α-internexin在胰腺内分泌肿瘤中的异常表达及其临床意义
研究目的胰腺内分泌肿瘤的分子发病机制未明。目前仍缺乏可靠的用于鉴别胰腺内分泌肿瘤良恶性的分子标志物。课题第二部分的研究目的是明确胰腺内分泌肿瘤是否存在α-internexin的表达及其表达调控机制;探讨α-internexin的表达是否可作为分子标志物用于鉴别该类肿瘤的良恶性和判断预后。
实验方法用免疫组织化学染色方法检测242例胰腺内分泌肿瘤α-internexin的表达,其中部分标本用免疫印迹法及反转录PCR法检测α-internexin蛋白及mRNA的表达进行确认。免疫印迹法检测17株细胞系该蛋白的表达。分别用反转录PCR、DNA测序和染色质免疫沉淀检测5-aza-dC作用前后人肿瘤细胞系α-internexin的mRNA表达、启动子甲基化及组蛋白修饰状态。分别用单因素和多因素分析方法对实验数据与临床病理学资料进行相关性统计分析,Kaplan-Meier法用于生存分析。
实验结果238个胰腺内分泌肿瘤中有132个肿瘤(55.4%)表达α-internexin蛋白,而对照组53个胰腺组织标本中仅1个标本(2%)表达该蛋白(P=9.97×10~(-14))。α-internexin的表达率在功能性与无功能性胰腺内分泌肿瘤之间有很显著地差异(71.4%vs.35.4%,P=2.36×10~(-8))。在恶性肿瘤、发生转移的肿瘤中α-internexin蛋白表达明显下降(P值分别为0.016、0.003)。α-internexin蛋白表达下降与患者因肿瘤死亡或肿瘤未治愈的不良预后均显著相关(P值分别为0.025或0.017)。
在多种人肿瘤细胞系中,α-internexin蛋白表达下降与其启动子甲基化显著相关(P=0.002)。但在正常胰腺和胰腺内分泌肿瘤的组织中发现α-internexin基因的启动子处于非甲基化状态,提示该基因在胰腺内分泌肿瘤中的表达调控与启动子甲基化与否无明显相关。
实验结论α-internexin表达下降可作为鉴别胰腺内分泌肿瘤的良恶性以及辅助判断患者的预后的分子标志物。α-internexin启动子甲基化是多种肿瘤细胞系中调控α-internexin蛋白表达的重要机制,但与胰腺内分泌肿瘤中α-internexin蛋白的表达无明显相关。
Purpose The molecular pathogenesis of sporadic insulinomas is unknown.There is a lack of biomarker to distinguish benign and malignant insulinoma.The aim of the first part of this study is to identify if mismatch repair genes are inactivated in insulinomas,which induce the microsatellite instability, and if the genetic/epigenetic alterations of the gene(s) as well as microsatellite instability could be used to distinguish benign and malignant insulinoma and to predict the outcome of the patients.
Experimental Design We detected microsatellite instability,allelic typing and promoter methylation by PCR.Denaturing high performance liquid chromatography(DHPLC) was used to analyze exon mutations which were further confirmed by sequencing.Expression of MLH1 and MSH2 gene in 61 insulinomas and paired normal tissues were tested by immunohistochemical staining.The data were correlated with clinical-pathological characteristics,and were analyzed by both univariate and multivariate statistical methods.
Results We found expression of MLH1 and MSH2 protein was reduced in 38%and 16%of 58 sporadic insulinomas,respectively.Promoter methylation and loss of heterozygosity(LOH) of MLH1 gene was found in 32% and 50%of sporadic insulinomas,respectively.Promoter methylation or both methylation and LOH of MLH1 were significantly associated with reduced expression of MLH1(P=0.041 and P=0.027,respectively).LOH of MSH2 gene was not found in sporadic insulinomas.A high rate of microsatellite instability (MSI-H) was found in 33%of sporadic insulinomas,which was correlated with the reduction of MLH1 or MSH2(P=0.006 and P=0.049,respectively).Reduced expression of both MLH1 and MSH2 were significantly correlated with MSI-H (P=0.004).Reduced expression of MLH1 or both MLH1 and MSH2 were significantly associated with tumor malignancy(P=0.008 or P=0.018).Although the rate of reduced expression of MSH2 in malignant tumors was higher than in benign tumors,the statistic difference was not significant(P=0.072).MSI-H was significantly associated with tumor malignancy and incurable insulinoma(P=2.6×10~(-5) and P=0.002,respectively).
Conclusion Allelic loss and promoter methylation contribute to the inactivation of MLH1 gene in sporadic insulinomas.Assessing alterations of MLH1 and MSH2 gene,as well as MSI-H,could be used to distinguish benign from malignant insulinomas and to predict the outcome of patients.The genetic/epigenetic silencing of MLH1 gene may play an important role in tumorigenesis in a subset of the tumors.
Purpose The molecular pathogenesis of pancreatic endocrine tumors is unknown.There is a lack of biomarker to distinguish benign and malignant pancreatic endocrine tumors.The aim of the second part of this study is to identify ifα-internexin expressed in pancreatic endocrine tumors,as well as analyzing the molecular mechanisms regulating the expression ofα-internexin; and to find if the alteration of the expression ofα-internexin could be used to distinguish benign and malignant pancreatic endocrine tumors and to predict the outcome of the patients.
Experimental Design Expression ofα-internexin in 242 pancreatic endocrine tumors were tested by immunohistochemical staining,and part of the tumors were also tested the expression of mRNA and protein ofα-internexin by RT-PCR and western blot,respectively.We also detected the protein expression ofα-internexin in 17 cell lines by western blot.Before and after treated with 5-aza-dC,the mRNA,promoter methylation and histon modification ofα-internexin in cell lines were detected by RT-PCR,sequencing and chromatin immunoprecipitation analysis,respectively.The data were correlated with clinical-pathological characteristics,and were analyzed by both univariate and multivariate statistical methods.Kaplan-Meier was used to analyse the cumulative survival.
Results We found 132 of 238(55.4%) pancreatic endocrine tumors expressedα-internexin,whereas only one of 53 pancreatic tissues expressed the protein(P = 9.97×10~(-14)).The percentage of the expression ofα-internexin was significantly higher in functional tumors than in non-functional ones(71.4%vs. 35.4%,P = 2.36×10~(-8)).Reduced expression ofα-internexin was significantly correlated with malignant tumors or tumors with metastasis(P=0.016 and P=0.003,respectively).Besides,reduced expression ofα-internexin was also significantly correlated with patients' outcome of dead with tumors or survival with tumors(P=0.025 and P=0.017,respectively).
Promoter methylation was significantly associated with reduced expression ofα-internexin in 14 tumor cell lines(P=0.002).However,promoter unmethylation status was found in both pancreatic endocrine tumors and normal pancreatic tissues,which indicated that promoter methylation was not play a role in the regulation mechanism of the expression ofα-internexin in pancreatic endocrine tumors.
Conclusion Reduced expression ofα-internexin could be used to distinguish benign from malignant pancreatic endocrine tumors and to predict the outcome of patients.Promoter methylation contributes to the inactivation ofα-internexin gene in many kinds of tumor cell lines,but it may not play an important role in pancreatic endocrine tumors.
引文
1.Corleto VD,Delle Fave G,Jensen RT.Molecular insights into gastrointestinal neuroendocrine tumours:importance and recent advances [J].Dig Liver Dis,2002,34(9):668-680.
2.Halfdanarson TR,Rubin J,Farnell MB,Grant CS,Petersen GM.Pancreatic endocrine neoplasms:epidemiology and prognosis of pancreatic endocrine tumors[J].Endocr Relat Cancer,2008,15(2):409-427.
3.House MG,Schulick RD.Endocrine tumors of the pancreas[J].Curr Opin Oncol,2006,18(1):23-29.
4.Jonkers YM,Ramaekers FC,Speel EJ.Molecular alterations during insulinoma tumorigenesis[J].Biochim Biophys Acta,2007,1775(2):313-332.
5.Oberg K,Eriksson B.Endocrine tumours of the pancreas[J].Best Pract Res Clin Gastroenterol,2005,19(5):753-781.
6.Phan GQ,Yeo CJ,Hruban RH,Lillemoe KD,Pitt HA,Cameron JL.Surgical experience with pancreatic and peripancreatic neuroendocrine tumors:review of 125 patients[J].J Gastrointest Surg,1998,2(5):472-482.
7.陈元方等.胃肠肽类激素基础与临床[M].北京:北京医科大学中国协和医科大学联合出版社,1997:665.
8.Chandrasekharappa SC,Guru SC,Manickam P,Olufemi SE,Collins FS,Emmert-Buck MR,Debelenko LV,Zhuang Z,Lubensky IA,Liotta LA et al.Positional cloning of the gene for multiple endocrine neoplasia-type 1[J].Science,1997,276(5311):404-407.
9.Jensen RT.Carcinoid and pancreatic endocrine tumors:recent advances in molecular pathogenesis,localization,and treatment[J].Curr Opin Oncol,2000,12(4):368-377.
10.Jensen R.Pancreatic endocrine tumors:recent advances[J].Ann Oncol,1999,10(Suppl 4):170-176.
11.Cupisti K,Hoppner W,Dotzenrath C,Simon D,Berndt I,Roher HD,Goretzki PE.Lack of MEN1 gene mutations in 27 sporadic insulinomas[J].Eur J Clin Invest,2000,30(4):325-329.
12.Jonkers YM,Claessen SM,Perren A,Schmid S,Komminoth P,Verhofstad AA,Hofland LJ,de Krijger RR,Slootweg PJ,Ramaekers FC et al. Chromosomal instability predicts metastatic disease in patients with insulinomas [J]. Endocr Relat Cancer,2005,12(2):435-447.
13. Zhuang Z, Vortmeyer AO, Pack S, Huang S, Pham TA, Wang C, Park WS, Agarwal SK, Debelenko LV, Kester M et al. Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas [J]. Cancer Res, 1997,57(21):4682-4686.
14. Zikusoka MN, Kidd M, Eick G, Latich I, Modlin IM. The molecular genetics of gastroenteropancreatic neuroendocrine tumors [J]. Cancer, 2005, 104(11):2292-2309.
15. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP et al. Gastroenteropancreatic neuroendocrine tumours[J].Lancet Oncol , 2008, 9(1): 61-72.
16. Mirkin SM. Expandable DNA repeats and human disease [J]. Nature, 2007, 447(7147):932-940.
17. Pickett HA, Baird DM, Hoff-Olsen P, Meling GI, Rognum TO, Shaw J, West KP, Royle NJ. Telomere instability detected in sporadic colon cancers,some showing mutations in a mismatch repair gene[J].Oncogene, 2004, 23(19):3434-3443.
18. Zhivotovsky B, Kroemer G. Apoptosis and genomic instability [J]. Nat Rev Mol Cell Biol, 2004, 5(9):752-762.
19. Macdonald GA, Greenson JK, Saito K, Cherian SP, Appelman HD, Boland CR. Microsatellite instability and loss of heterozygosity at DNA mismatch repair gene loci occurs during hepatic carcinogenesis [J]. Hepatology, 1998, 28(1):90-97.
20. Chan TL, Yuen ST, Kong CK, Chan YW, Chan AS, Ng WF, Tsui WY, Lo MW, Tarn WY, Li VS et al. Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer [J]. Nat Genet, 2006, 38(10):1178-1183.
21. Hemminki A, Peltomaki P, Mecklin JP, Jarvinen H, Salovaara R, Nystrom-Lahti M, de la Chapelle A, Aaltonen LA. Loss of the wild type MLH1 gene is a feature of hereditary nonpolyposis colorectal cancer [J]. Nat Genet, 1994, 8(4):405-410.
22. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, Markowitz S, Willson JK, Hamilton SR, Kinzler KW et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma [J]. Proc Natl Acad Sci U S A, 1998, 95(12):6870-6875.
23. Murata H, Khattar NH, Kang Y, Gu L, Li GM. Genetic and epigenetic modification of mismatch repair genes hMSH2 and hMLH1 in sporadic breast cancer with microsatellite instability [ J ]. Oncogene, 2002, 21(37):5696-5703.
24. Salovaara R, Loukola A, Kristo P, Kaariainen H, Ahtola H, Eskelinen M, Harkonen N, Julkunen R, Kangas E, Ojala S et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer [J]. J Clin Oncol, 2000, 18(11):2193-2200.
25. Veigl ML, Kasturi L, Olechnowicz J, Ma AH, Lutterbaugh JD, Periyasamy S, Li GM, Drummond J, Modrich PL, Sedwick WD et al. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers[J]. Proc Natl Acad Sci U SA,1998,95(15):8698-8702.
26. Wang YC, Lu YP, Tseng RC, Lin RK, Chang JW, Chen JT, Shih CM, Chen CY. Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples [J]. J Clin Invest, 2003, 111(6):887-895.
27. House MG, Herman JG, Guo MZ, Hooker CM, Schulick RD, Cameron JL, Hruban RH, Maitra A, Yeo CJ. Prognostic value of hMLH1 methylation and microsatellite instability in pancreatic endocrine neoplasms [J]. Surgery, 2003, 134(6):902-908
28. House MG, Herman JG, Guo MZ, Hooker CM, Schulick RD, Lillemoe KD, Cameron JL, Hruban RH, Maitra A, Yeo CJ. Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms [J]. Ann Surg, 2003, 238(3):423-431.
29. Yang YM, Liu TH, Chen YJ, Jiang WJ, Qian JM, Lu X, Gao J, Wu SF, Sang XT, Chen J. Chromosome 1q loss of heterozygosity frequently occurs in sporadic insulinomas and is associated with tumor malignancy [J]. Int J Cancer, 2005, 117(2):234-240.
30. Jiang WJ, Liu TH, Chen J, Gao J, Wu SF, Chen YJ. Frequent loss of heterozygosity at MEN-1 gene and chromosome 22q in insulinomas and its significance [J]. Zhonghua yi xue za zhi, 2004, 84(20): 1705-1709.
31． 萨姆布鲁克J,拉塞尔D．W．著,黄培堂等译．分子克隆实验指南(第三版)[M]．北京：科学出版社,2002．
32. Eads CA, Laird PW. Combined bisulfite restriction analysis (COBRA) [J]. Methods Mol Biol, 2002, 200:71-85.
33. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands [J]. Proc Natl Acad Sci U S A, 1996, 93(18):9821-9826.
34. Deng DJ,Zhou J,Zhu BD,Ji JF,Harper JC,Powell SM. Silencing-specific methylation and single nucleotide polymorphism of hMLH1 promoter in gastric carcinomas [J]. World J Gastroenterol, 2003, 9(1):26-29.
35. Wang RY, Gehrke CW, Ehrlich M. Comparison of bisulfite modification of 5-methyldeoxycytidine and deoxycytidine residues [J]. Nucleic Acids Res, 1980, 8(20):4777-4790.
36. Deng G, Chen A, Hong J, Chae HS, Kim YS. Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression [J]. Cancer Res, 1999, 59(9):2029-2033.
37. Deng D,Deng G,Smith MF,Zhou J,Xin H,Powell SM,Lu Y. Simultaneous detection of CpG methylation and single nucleotide polymorphism by denaturing high performance liquid chromatography [J]. Nucleic Acids Res,2002,30(3):E13.
38. Chen YJ,Vortmeyer A.Zhuang Z,Huang S,Jensen RT. Loss of heterozygosity of chromosome 1q in gastrinomas: occurrence and prognostic significance [J]. Cancer Res, 2003, 63(4):817-823.
39. Xicola RM,LIor X,Pons E,Castells A,AIenda C,Pinol V,Andreu M, Castellvi-Bel S,Paya A,Jover R et al. Performance of different microsatellite marker panels for detection of mismatch repair-deficient colorectal tumors [J]. J Natl Cancer Inst, 2007, 99(3):244-252.
40. Zauber NP, Sabbath-Solitare M, Marotta SP, McMahon L, Bishop DT. Comparison of allelic ratios from paired blood and paraffin-embedded normal tissue for use in a polymerase chain reaction to assess loss of heterozygosity [J]. Mol Diagn, 1999, 4(1):29-35.
41. Holinski-Feder E, Muller-Koch Y, Friedl W, Moeslein G, Keller G, Plaschke J, Ballhausen W, Gross M, Baldwin-Jedele K, Jungck M et al. DHPLC mutation analysis of the hereditary nonpolyposis colon cancer (HNPCC) genes hMLH1 and hMSH2 [J]. J Biochem Biophys Methods, 2001, 47(1-2):21-32.
42. Kurzawski G,Safranow K,Suchy J,Chlubek D,Scott RJ,Lubinski J. Mutation analysis of MLH1 and MSH2 genes performed by denaturing high-performance liquid chromatography[J].J Biochem Biophys Methods,2002,51(1):89-100.
43.Bahrami AR,Dickman MJ,Matin MM,Ashby JR,Brown PE,Conroy M J,Fowler GJ,Rose JP,Sheikh QI,Yeung AT et al.Use of fluorescent DNA-intercalating dyes in the analysis of DNA via ion-pair reversed-phase denaturing high-performance liquid chromatography[J].Anal Biochem,2002,309(2):248-252.
44.蒋卫君,刘彤华,陈杰,等.胰岛素瘤频发MEN-1抑癌基因及22q的杂合缺失及其意义[J].中华医学杂志,2004,84:1705-1709.
45.吴海燕,赵大春,梅玫,陈杰,卢欣,杜顺达,周春宇,桑新亭,陈原稼.Ki-67在胰岛素瘤中的表达及其意义[J].胃肠病学,2008,13(4):209-212.
46.Gibril F,Jensen RT.Clinical Gastroenterology and Hepatology[M].London:ELSEVIER,2005:811-822.
47.Gumbs AA,Moore PS,Falconi M,Bassi C,Beghelli S,Modlin I,Scarpa A.Review of the clinical,histological,and molecular aspects of pancreatic endocrine neoplasms[J].J Surg Oncol,2002,81(1):45-53.
48.De Schutter H,Spaepen M,Mc Bride WH,Nuyts S.The clinical relevance of microsatellite alterations in head and neck squamous cell carcinoma:a critical review[J].Eur J Hum Genet,2007,15(7):734-741.
49.Kaz A,Kim YH,Dzieciatkowski S,Lynch H,Watson P,Kay Washington M,Lin L,Grady WM.Evidence for the role of aberrant DNA methylation in the pathogenesis of Lynch syndrome adenomas[J].Int J Cancer,2007,120(9):1922-1929.
50.Velasco A,Corvalan A,Wistuba,Ⅱ,Riquelme E,Chuaqui R,Majerson A,Leach FS.Mismatch repair expression in testicular cancer predicts recurrence and survival[J].Int J Cancer,2008,122(8):1774-1777.
51.Arnold CN,Sosnowski A,Schmitt-Graff A,Arnold R,Blum HE.Analysis of molecular pathways in sporadic neuroendocrine tumors of the gastro-entero-pancreatic system[J].Int J Cancer,2007,120(10):2157-2164.
52.Capel E,Flejou JF,Hamelin R.Assessment of MLH1 promoter methylation in relation to gene expression requires specific analysis[J].Oncogene,2007,26(54):7596-7600.
53.Ollikainen M,Hannelius U,Lindgren CM,Abdel-Rahman WM,Kere J, Peltomaki P. Mechanisms of inactivation of MLH1 in hereditary nonpolyposis colorectal carcinoma: a novel approach [J]. Oncogene,2007,26(31):4541-4549.
54. Park SJ, Rashid A, Lee JH, Kim SG, Hamilton SR, Wu TT. Frequent CpG island methylation in serrated adenomas of the colorectum [J]. Am J Pathol, 2003, 162(3):815-822.
55. Kim GP, Colangelo LH, Wieand HS, Paik S, Kirsch IR, Wolmark N, Allegra CJ. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study [J]. J Clin Oncol, 2007, 25(7):767-772.
56. Chen J, Sadowski I. Identification of the mismatch repair genes PMS2 and MLH1 as p53 target genes by using serial analysis of binding elements [J]. Proc Natl Acad Sci U S A, 2005, 102(13):4813-4818.
57. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis [ J ]. J Clin Oncol, 2005, 23(3):609-618.
1.刘丹.胰岛素瘤和正常胰腺蛋白质组差异比较的初步研究[D].北京:北京协和医学院,2005:
2.Ho CL,Liem RK.Intermediate filaments in the nervous system:implications in cancer[J].Cancer Metastasis Rev,1996,15(4):483-497.
3.Barry DM,Millecamps S,Julien JP,Garcia ML.New movements in neurofilament transport,turnover and disease[J].Exp Cell Res,2007,313(10):2110-2120.
4.Yuan A,Rao MV,Sasaki T,Chen Y,Kumar A,Veeranna,Liem RK,Eyer J,Peterson AC,Julien JP et al.Alpha-internexin is structurally and functionally associated with the neurofilament triplet proteins in the mature CNS[J].J Neurosci,2006,26(39):10006-10019.
5.Rauch U,Klotz M,Maas-Omlor S,Wink E,Hansgen A,Hagl C,Holland-Cunz S,Schafer KH.Expression of intermediate filament proteins and neuronal markers in the human fetal gut[J].J Histochem Cytochem,2006,54(1):39-46.
6.Behrends U,Jandl T,Golbeck A,Lechner B,Muller-Weihrich S,Schmid I,Till H,Berthold F,Voltz R,Mautner JM.Novel products of the HUD,HUC,NNP-1and alpha-internexin genes identified by autologous antibody screening of a pediatric neuroblastoma library[J].Int J Cancer,2002,100(6):669-677.
7.Chan SO,Runko E,Anyane-Yeboa K,Ko L,Chiu FC.Calcium ionophore-induced degradation of neurofilament and cell death in MSN neuroblastoma cells[J].Neurochem Res,1998,23(3):393-400.
8.Armstrong RA,Cairns NJ.Spatial patterns of the pathological changes in neuronal intermediate filament inclusion disease(NIFID):an alpha-internexin immunohistochemical study[J].J Neural Transm,2007,114(4):451-456.
9.Foley J,Witte D,Chiu FC,Parysek LM.Expression of the neural intermediate filament proteins peripherin and eurofilament-66 /alpha-internexin in neuroblastoma[J].Lab Invest,1994,71(2):193-199.
10.Willoughby V,Sonawala A,Werlang-Perurena A,Donner LR.A comparative immunohistochemical analysis of small round cell tumors of childhood:utility of peripherin and alpha-internexin as markers for neuroblastomas[J].Appl Immunohistochem Mol Morphol,2008,16(4):344-348.
11.Donner LR,Teshima I.Peripheral medulloepithelioma:an immunohistochemical,ultrastructural,and cytogenetic study of a rare,chemotherapy-sensitive,pediatric tumor[J].Am J Pathol,2003,27(7):1008-1012
12.Ikeda H,Yoshimoto T.Immunohistochemical study of anaplastic meningioma with special reference to the phenotypic change of intermediate filament protein[J].Ann Diagn Pathol,2003,7(4):214-222.
13.Kaya B,Mena H,Miettinen M,Rushing EJ.Alpha-internexin expression in medulloblastomas and atypical teratoid-rhabdoid tumors[J].Clin Neuropathol,2003,22(5):215-221.
14.萨姆布鲁克J,拉塞尔D.W.著,黄培堂等译.分子克隆实验指南(第三版)[M].北京:科学出版社,2002.
15.鄂征.组织培养技术及其在医学研究中的应用[M].北京:中国协和医科大学出版社,1999.
16.Halfdanarson TR,Rubin J,Farnell MB,Grant CS,Petersen GM.Pancreatic endocrine neoplasms:epidemiology and prognosis of pancreatic endocrine tumors[J].Endocr Relat Cancer,2008,15(2):409-427.
17.House MG,Schulick RD.Endocrine tumors of the pancreas[J].Curr Opin Oncol,2006,18(1):23-29.
18.Jonkers YM,Ramaekers FC,Speel EJ.Molecular alterations during insulinoma tumorigenesis[J].Biochim Biophys Acta,2007,1775(2):313-332.
19.Oberg K,Eriksson B.Endocrine tumours of the pancreas[J].Best Pract Res Clin Gastroenterol,2005,19(5):753-781.
20.Jensen RT.Carcinoid and pancreatic endocrine tumors:recent advances in molecular pathogenesis,localization,and treatment[J].Curr Opin Oncol,2000,12(4):368-377.
21.Jensen R.Pancreatic endocrine tumors:recent advances[J].Ann Oncol,1999,10(Suppl 4):170-176.
22.Corleto VD,Delle Fave G,Jensen RT.Molecular insights into gastrointestinal neuroendocrine tumours:importance and recent advances [J].Dig Liver Dis,2002,34(9):668-680.
23. Cupisti K,Hoppner W,Dotzenrath C,Simon D,Berndt I, Roher HD, Goretzki PE. Lack of MEN1 gene mutations in 27 sporadic insulinomas [J]. Eur J Clin Invest, 2000, 30(4):325-329.
24. Jonkers YM,CIaessen SM,Perren A,Schmid S,Komminoth P, Verhofstad AA,Hofland LJ,de Krijger RR,SIootweg PJ, Ramaekers FC et al. Chromosomal instability predicts metastatic disease in patients with insulinomas [J]. Endocr Relat Cancer, 2005, 12(2):435-447.
25. Zhuang Z, Vortmeyer AO, Pack S, Huang S, Pham TA, Wang C, Park WS, Agarwal SK, Debelenko LV, Kester M et al. Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas [J]. Cancer Res, 1997, 57(21):4682-4686.
26. Zikusoka MN, Kidd M, Eick G, Latich I, Modlin IM. The molecular genetics of gastroenteropancreatic neuroendocrine tumors [J]. Cancer, 2005, 104(11):2292-2309.
27. Gumbs AA, Moore PS, Falconi M, Bassi C, Beghelli S, Modlin I, Scarpa A. Review of the clinical, histological, and molecular aspects of pancreatic endocrine neoplasms [J]. J Surg Oncol, 2002, 81(1):45-53
28. Mansour JC, Chen H. Pancreatic endocrine tumors [J]. J Surg Res, 2004, 120(1):139-161.
29. Ducray F,Criniere E,ldbaih A,Mokhtari K,Marie Y.Paris S,Navarro S, Laigle-Donadey F,Dehais C,Thillet J et al. alpha-Internexin expression identifies 1p19q codeleted gliomas [J]. Neurology, 2009, 72(2):156-161.
30. Pape UF,Bemdt U,Muller-Nordhorn J,Bohmig M,Roll S,Koch M, Willich SN,Wiedenmann B. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours[J]. Endocr Relat Cancer, 2008, 15(4): 1083-1097.
31. Lepage C, Rachet B, Coleman MP. Survival from malignant digestive endocrine tumors in England and Wales: a population-based study [J]. Gastroenterology, 2007, 132(3):899-904.
32. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? [J]. Nat Rev Cancer, 2006, 6(2):107-116.
33. Santos-Reboucas CB, Pimentel MM: Implication of abnormal epigenetic patterns for human diseases [J]. Eur J Hum Genet, 2007, 15(1): 10-17.
34. Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells[J].Nat Rev Cancer,2005,5(3):223-231.
35.沈翊琲.染色体与表观遗传调控[M],北京:高等教育出版社:2006,35-7536.Fraga M F,Ballestar E,Villar-Garea A,Boix-Chornet M,Espada J,Schotta G,Bonaldi T,Haydon C,Ropero S,Petrie K et al.Loss of acetylation at Lys16and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer[J].Nat Genet,2005,37(4):391-400.
1.Oberg K,Eriksson B.Endocrine tumours of the pancreas[J].Best Pract Res Clin Gastroenterol,2005,19(5):753-781.
2.Jonkers YM,Ramaekers FC,Speel EJ.Molecular alterations during insulinoma tumorigenesis[J].Biochim Biophys Acta,2007,1775(2):313-332.
3.陈元方等.胃肠肽类激素基础与临床[M].北京:北京医科大学中国协和医科大学联合出版社,1997:665.
4.陈原稼,梅玫.胰腺内分泌肿瘤临床、分子生物学和遗传学预后指标[J].胰腺病学,2004,4:182-186.
5.Jensen R.Pancreatic endocrine tumors:recent advances[J].Ann Oncol,1999,10(Suppl 4):170-176.
6.Perren A,Anlauf M,Henopp T,Rudolph T,Schmitt A,Raffel A,Gimm O,Weihe E,Knoefel WT,Dralle H et al.Multiple endocrine neoplasia type 1(MEN1):loss of one MEN1 allele in tumors and monohormonal endocrine cell clusters but not in islet hyperplasia of the pancreas[J].J Clin Endocrinol Metab,2007,92(3):1118-1128.
7.Zhao Y,Wang X,Yang B,Xiao Y,Cai L,Zhong S,Zhu Y.Pancreatic insulinomas:experience in 220 patients[J].Zhonghua wai ke za zhi,2000,38(1):10-13.
8.张太平,赵玉沛,郐占波等:胰岛素瘤误诊原因探讨和处理对策(附71例报告).胰腺病学,2002,2:31-33.
9.Halfdanarson TR,Rubin J,Farnell MB,Grant CS,Petersen GM.Pancreatic endocrine neoplasms:epidemiology and prognosis of pancreatic endocrine tumors[J].Endocr Relat Cancer,2008,15(2):409-427.
10.Berger AC,Gibril F,Venzon DJ,Doppman J L,Norton JA,Bartlett DL,Libutti SK,Jensen RT,Alexander HR,Prognostic value of initial fasting serum gastnn levels in patients with Zollinger-Ellison syndrome[J].J Clin Oncol,2001,19(12):3051-3057.
11.Yu F,Venzon DJ,Serrano J,Goebel SU,Doppman JL,Gibril F,Jensen RT.Prospective study of the clinical course,prognostic factors,causes of death,and survival in patients with long-standing Zollinger-Ellison syndrome[J].J Clin Oncol,1999,17(2):615-630.
12. Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B: Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution [J]. Clin Cancer Res, 2008,14(23):7798-7803.
13. La Rosa S, Klersy C, Uccella S, Dainese L, Albarello L, Sonzogni A, Doglioni C, Capella C, Solcia E. Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors [J]. Hum Pathol, 2009, 40(1):30-40.
14. Bettini R, Boninsegna L, Mantovani W, Capelli P, Bassi C, Pederzoli P, Delle Fave GF, Panzuto F, Scarpa A, Falconi M. Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours[J]. Ann Oncol, 2008, 19(5):903-908.
15. Diaz-Rubio JL, Duarte-Rojo A, Saqui-Salces M, Gamboa-Dominguez A, Robles-Diaz G. Cellular proliferative fraction measured with topoisomerase Ilalpha predicts malignancy in endocrine pancreatic tumors [J]. Arch Pathol Lab Med, 2004, 128(4):426-429.
16. You DD, Lee HG, Paik KY, Heo JS, Choi SH, Choi DW. The outcomes after surgical resection in pancreatic endocrine tumors: An institutional experience [J]. Eur J Surg Oncol, 2009.
17. Chung JC, Choi DW, Jo SH, Heo JS, Choi SH, Kim YI. Malignant nonfunctioning endocrine tumors of the pancreas: predictive factors for survival after surgical treatment [J]. World J Surg, 2007, 31 (3):579-585.
18. Hochwald SN, Zee S, Conlon KC, Colleoni R, Louie O, Brennan MF, Klimstra DS. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups [J]. J Clin Oncol, 2002, 20(11 ):2633-2642.
19. Marion-Audibert AM, Barel C, Gouysse G, Dumortier J, Pilleul F, Pourreyron C, Hervieu V, Poncet G, Lombard-Bohas C, Chayvialle JA et al. Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors [J]. Gastroenterology, 2003, 125(4): 1094-1104.
20. Takahashi Y, Akishima-Fukasawa Y, Kobayashi N, Sano T, Kosuge T, Nimura Y, Kanai Y, Hiraoka N. Prognostic value of tumor architecture, tumor-associated vascular characteristics, and expression of angiogenic molecules in pancreatic endocrine tumors [J]. Clin Cancer Res, 2007, 13(1):187-196.
21. Heitz PL) KP, Perren A, et al. Tumours of the endocrine pancreas [M]. Lyon: IARC Press; 2004.
22. Schmitt AM, Anlauf M, Rousson V, Schmid S, Kofler A, Riniker F, Bauersfeld J, Barghorn A, Probst-Hensch NM, Moch H et al. WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors [J]. Am J Surg Pathol, 2007, 31(11):1677-1682.
23. Jensen RT. Carcinoid and pancreatic endocrine tumors: recent advances in molecular pathogenesis, localization, and treatment [J]. Curr Opin Oncol, 2000, 12(4):368-377.
24. Serrano J, Goebel SU, Peghini PL, Lubensky IA, Gibril F, Jensen RT. Alterations in the p16INK4a/CDKN2A tumor suppressor gene in gastrinomas [J]. J Clin Endocrinol Metab, 2000, 85(11):4146-4156.
25. Corleto VD, Delle Fave G, Jensen RT. Molecular insights into gastrointestinal neuroendocrine tumours: importance and recent advances [J]. Dig Liver Dis, 2002, 34(9):668-680.
26. House MG, Schulick RD. Endocrine tumors of the pancreas [J]. Curr Opin Oncol, 2006, 18(1):23-29.
27. Zhuang Z, Vortmeyer AO, Pack S, Huang S, Pham TA, Wang C, Park WS, Agarwal SK, Debelenko LV, Kester M et al. Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas [J]. Cancer Res, 1997, 57(21):4682-4686.
28. Peghini PL, Iwamoto M, Raffeld M, Chen YJ, Goebel SU, Serrano J, Jensen RT. Overexpression of epidermal growth factor and hepatocyte growth factor receptors in a proportion of gastrinomas correlates with aggressive growth and lower curability [J]. Clin Cancer Res, 2002, 8(7):2273-2285.
29. Goebel SU, Iwamoto M, Raffeld M, Gibril F, Hou W, Serrano J, Jensen RT. Her-2/neu expression and gene amplification in gastrinomas: correlations with tumor biology, growth, and aggressiveness [J]. Cancer Res. 2002, 62(13):3702-3710.
30. Furukawa M, Raffeld M, Mateo C, Sakamoto A, Moody TW, Ito T, Venzon DJ, Serrano J, Jensen RT. Increased expression of insulin-like growth factor I and/or its receptor in gastrinomas is associated with low curability, increased growth, and development of metastases [J]. Clin Cancer Res, 2005, 11(9):3233-3242.
31. Hansel DE, Rahman A, Hermans J, de Krijger RR, Ashfaq R, Yeo CJ, Cameron JL, Maitra A. Liver metastases arising from well-differentiated pancreatic endocrine neoplasms demonstrate increased VEGF-C expression [J]. Mod Pathol, 2003, 16(7):652-659.
32. Deshpande V, Fernandez-del Castillo C, Muzikansky A, Deshpande A, Zukerberg L, Warshaw AL, Lauwers GY. Cytokeratin 19 is a powerful predictor of survival in pancreatic endocrine tumors [J]. Am J Surg Pathol, 2004, 28(9): 1145-1153.
33. La Rosa S, Rigoli E, Uccella S, Novario R, Capella C. Prognostic and biological significance of cytokeratin 19 in pancreatic endocrine tumours [J]. Histopathology, 2007, 50(5):597-606.
34. Grabowski P, Griss S, Arnold CN, Horsch D, Goke R, Arnold R, Heine B, Stein H, Zeitz M, Scherubl H. Nuclear survivin is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumor disease [J]. Neuroendocrinology, 2005, 81(1): 1-9.
35. Dalai I, Missiaglia E, Barbi S, Butturini G, Doglioni C, Falconi M, Scarpa A. Low expression of ARHl is associated with shorter progression-free survival in pancreatic endocrine tumors [J]. Neoplasia, 2007, 9(3):181-183.
36. Heitz PU, Kasper M, Kloppel G, Polak JM, Vaitukaitis JL. Glycoprotein-hormone alpha-chain production by pancreatic endocrine tumors: a specific marker for malignancy. Immunocytochemical analysis of tumors of 155 patients [J]. Cancer, 1983, 51 (2):277-282.
37. Graeme-Cook F, Bell DA, Flotte TJ, Preffer F, Pastel-Levy C, Nardi G, Compton C. Aneuploidy in pancreatic insulinomas does not predict malignancy [J]. Cancer, 1990, 66(11):2365-2368.
38. AN A, Serra S, Asa SL, Chetty R. The predictive value of CK19 and CD99 in pancreatic endocrine tumors [J]. Am J Surg Pathol, 2006, 30(12):1588-1594.
39. Rahman A, Maitra A, Ashfaq R, Yeo CJ, Cameron JL, Hansel DE. Loss of p27 nuclear expression in a prognostically favorable subset of well-differentiated pancreatic endocrine neoplasms[J]. Am J Clin Pathol, 2003, 120(5):685-690.
40. Ohike N, Morohoshi T. Immunohistochemical analysis of cyclooxygenase (COX)-2 expression in pancreatic endocrine tumors:association with tumor progression and proliferation[J].Pathol Int,2001,51(10):770-777.
41.Deschamps L,Handra-Luca A,O'Toole D,Sauvanet A,Ruszniewski P,Belghiti J,Bedossa P,Couvelard A.CD10 expression in pancreatic endocrine tumors:correlation with prognostic factors and survival[J].Hum Pathol,2006,37(7):802-808.
42.Imam H,Eriksson B,Oberg K.Expression of CD44 variant isoforms and association to the benign form of endocrine pancreatic tumours[J].Ann Oncol,2000,11(3):295-300.
43.Guo SS,Wu AY,Sawicki MP.Deletion of chromosome 1,but not mutation of MEN-1,predicts prognosis in sporadic pancreatic endocrine tumors[J].World J Surg,2002,26(7):843-847.
44.Chen Y J,Vortmeyer A,Zhuang Z,Huang S,Jensen RT.Loss of heterozygosity of chromosome 1q in gastrinomas:occurrence and prognostic significance[J].Cancer Res,2003,63(4):817-823.
45.Yang YM,Liu TH,Chen Y J,Jiang W J,Qian JM,Lu X,Gao J,Wu SF,Sang XT,Chen J.Chromosome 1q loss of heterozygosity frequently occurs in sporadic insulinomas and is associated with tumor malignancy[J].Int J Cancer,2005,117(2):234-240.
46.蒋卫君,刘彤华,陈杰等.胰岛素瘤频发MEN-1抑癌基因及22q的杂合缺失及其意义[J].中华医学杂志,2004,84:1705-1709.
47.Pizzi S,D'Adda T,Azzoni C,Rindi G,Grigolato P,Pasquali C,Corleto VD,Delle Fave G,Bordi C.Malignancy-associated allelic losses on the X-chromosome in foregut but not in midgut endocrine tumours[J].J Pathol,2002,196(4):401-407.
48.Missiaglia E,Moore PS,Williamson J,Lemoine NR,Falconi M,Zamboni G,Scarpa A.Sex chromosome anomalies in pancreatic endocrine tumors[J].Int J Cancer,2002,98(4):532-538.
49.Chen Y J,Vortmeyer A,Zhuang Z,Gibril F,Jensen RT.X-chromosome loss of heterozygosity frequently occurs in gastrinomas and is correlated with aggressive tumor growth[J].Cancer,2004,100(7):1379-1387.
50.Guo SS,Arora C,Shimoide AT,Sawicki MP.Frequent deletion of chromosome 3 in malignant sporadic pancreatic endocrine tumors[J].Mol Cell Endocrinol,2002,190(1-2):109-114.
51. Barghorn A, Komminoth P, Bachmann D, Rutimann K, Saremaslani P, Muletta-Feurer S, Perren A, Roth J, Heitz PU, Speel EJ. Deletion at 3p25.3-p23 is frequently encountered in endocrine pancreatic tumours and is associated with metastatic progression [J]. J Pathol, 2001, 194(4):451-458.
52. Hessman O, Lindberg D, Einarsson A, Lillhager P, Carling T, Grimelius L, Eriksson B, Akerstrom G, Westin G, Skogseid B. Genetic alterations on 3p, 11q13, and 18q in nonfamilial and MEN 1-associated pancreatic endocrine tumors [J]. Genes chromosomes cancer, 1999, 26(3):258-264.
53. Barghorn A, Speel EJ, Farspour B, Saremaslani P, Schmid S, Perren A, Roth J, Heitz PU, Komminoth P. Putative tumor suppressor loci at 6q22 and 6q23-q24 are involved in the malignant progression of sporadic endocrine pancreatic tumors [J]. Am J Pathol, 2001, 158(6):1903-1911.
54. Speel EJ, Scheidweiler AF, Zhao J, Matter C, Saremaslani P, Roth J, Heitz PU, Komminoth P. Genetic evidence for early divergence of small functioning and nonfunctioning endocrine pancreatic tumors: gain of 9Q34 is an early event in insulinomas [J]. Cancer Res, 2001, 61(13):5186-5192.
55. Beghelli S, Pelosi G, Zamboni G, Falconi M, lacono C, Bordi C, Scarpa A. Pancreatic endocrine tumours: evidence for a tumour suppressor pathogenesis and for a tumour suppressor gene on chromosome 17p [J]. J Pathol, 1998, 186(1):41-50.
56. House MG, Herman JG, Guo MZ, Hooker CM, Schulick RD, Lillemoe KD, Cameron JL, Hruban RH, Maitra A, Yeo CJ. Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms [J]. Ann Surg, 2003, 238(3):423-431
57. House MG, Herman JG, Guo MZ, Hooker CM, Schulick RD, Cameron JL, Hruban RH, Maitra A, Yeo CJ. Prognostic value of hMLH1 methylation and microsatellite instability in pancreatic endocrine neoplasms [J]. Surgery, 2003, 134(6):902-908.
58. Liu L, Broaddus RR, Yao JC, Xie S, White JA, Wu TT, Hamilton SR, Rashid A. Epigenetic alterations in neuroendocrine tumors: methylation of RAS-association domain family 1, isoform A and p16 genes are associated with metastasis [J]. Mod Pathol, 2005, 18(12):1632-1640.
2.Halfdanarson TR,Rubin J,Farnell MB,Grant CS,Petersen GM.Pancreatic endocrine neoplasms:epidemiology and prognosis of pancreatic endocrine tumors[J].Endocr Relat Cancer,2008,15(2):409-427.
3.House MG,Schulick RD.Endocrine tumors of the pancreas[J].Curr Opin Oncol,2006,18(1):23-29.
4.Jonkers YM,Ramaekers FC,Speel EJ.Molecular alterations during insulinoma tumorigenesis[J].Biochim Biophys Acta,2007,1775(2):313-332.
5.Oberg K,Eriksson B.Endocrine tumours of the pancreas[J].Best Pract Res Clin Gastroenterol,2005,19(5):753-781.
6.Phan GQ,Yeo CJ,Hruban RH,Lillemoe KD,Pitt HA,Cameron JL.Surgical experience with pancreatic and peripancreatic neuroendocrine tumors:review of 125 patients[J].J Gastrointest Surg,1998,2(5):472-482.
7.陈元方等.胃肠肽类激素基础与临床[M].北京:北京医科大学中国协和医科大学联合出版社,1997:665.
8.Chandrasekharappa SC,Guru SC,Manickam P,Olufemi SE,Collins FS,Emmert-Buck MR,Debelenko LV,Zhuang Z,Lubensky IA,Liotta LA et al.Positional cloning of the gene for multiple endocrine neoplasia-type 1[J].Science,1997,276(5311):404-407.
9.Jensen RT.Carcinoid and pancreatic endocrine tumors:recent advances in molecular pathogenesis,localization,and treatment[J].Curr Opin Oncol,2000,12(4):368-377.
10.Jensen R.Pancreatic endocrine tumors:recent advances[J].Ann Oncol,1999,10(Suppl 4):170-176.
11.Cupisti K,Hoppner W,Dotzenrath C,Simon D,Berndt I,Roher HD,Goretzki PE.Lack of MEN1 gene mutations in 27 sporadic insulinomas[J].Eur J Clin Invest,2000,30(4):325-329.
12.Jonkers YM,Claessen SM,Perren A,Schmid S,Komminoth P,Verhofstad AA,Hofland LJ,de Krijger RR,Slootweg PJ,Ramaekers FC et al. Chromosomal instability predicts metastatic disease in patients with insulinomas [J]. Endocr Relat Cancer,2005,12(2):435-447.
13. Zhuang Z, Vortmeyer AO, Pack S, Huang S, Pham TA, Wang C, Park WS, Agarwal SK, Debelenko LV, Kester M et al. Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas [J]. Cancer Res, 1997,57(21):4682-4686.
14. Zikusoka MN, Kidd M, Eick G, Latich I, Modlin IM. The molecular genetics of gastroenteropancreatic neuroendocrine tumors [J]. Cancer, 2005, 104(11):2292-2309.
15. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP et al. Gastroenteropancreatic neuroendocrine tumours[J].Lancet Oncol , 2008, 9(1): 61-72.
16. Mirkin SM. Expandable DNA repeats and human disease [J]. Nature, 2007, 447(7147):932-940.
17. Pickett HA, Baird DM, Hoff-Olsen P, Meling GI, Rognum TO, Shaw J, West KP, Royle NJ. Telomere instability detected in sporadic colon cancers,some showing mutations in a mismatch repair gene[J].Oncogene, 2004, 23(19):3434-3443.
18. Zhivotovsky B, Kroemer G. Apoptosis and genomic instability [J]. Nat Rev Mol Cell Biol, 2004, 5(9):752-762.
19. Macdonald GA, Greenson JK, Saito K, Cherian SP, Appelman HD, Boland CR. Microsatellite instability and loss of heterozygosity at DNA mismatch repair gene loci occurs during hepatic carcinogenesis [J]. Hepatology, 1998, 28(1):90-97.
20. Chan TL, Yuen ST, Kong CK, Chan YW, Chan AS, Ng WF, Tsui WY, Lo MW, Tarn WY, Li VS et al. Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer [J]. Nat Genet, 2006, 38(10):1178-1183.
21. Hemminki A, Peltomaki P, Mecklin JP, Jarvinen H, Salovaara R, Nystrom-Lahti M, de la Chapelle A, Aaltonen LA. Loss of the wild type MLH1 gene is a feature of hereditary nonpolyposis colorectal cancer [J]. Nat Genet, 1994, 8(4):405-410.
22. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, Markowitz S, Willson JK, Hamilton SR, Kinzler KW et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma [J]. Proc Natl Acad Sci U S A, 1998, 95(12):6870-6875.
23. Murata H, Khattar NH, Kang Y, Gu L, Li GM. Genetic and epigenetic modification of mismatch repair genes hMSH2 and hMLH1 in sporadic breast cancer with microsatellite instability [ J ]. Oncogene, 2002, 21(37):5696-5703.
24. Salovaara R, Loukola A, Kristo P, Kaariainen H, Ahtola H, Eskelinen M, Harkonen N, Julkunen R, Kangas E, Ojala S et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer [J]. J Clin Oncol, 2000, 18(11):2193-2200.
25. Veigl ML, Kasturi L, Olechnowicz J, Ma AH, Lutterbaugh JD, Periyasamy S, Li GM, Drummond J, Modrich PL, Sedwick WD et al. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers[J]. Proc Natl Acad Sci U SA,1998,95(15):8698-8702.
26. Wang YC, Lu YP, Tseng RC, Lin RK, Chang JW, Chen JT, Shih CM, Chen CY. Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples [J]. J Clin Invest, 2003, 111(6):887-895.
27. House MG, Herman JG, Guo MZ, Hooker CM, Schulick RD, Cameron JL, Hruban RH, Maitra A, Yeo CJ. Prognostic value of hMLH1 methylation and microsatellite instability in pancreatic endocrine neoplasms [J]. Surgery, 2003, 134(6):902-908
28. House MG, Herman JG, Guo MZ, Hooker CM, Schulick RD, Lillemoe KD, Cameron JL, Hruban RH, Maitra A, Yeo CJ. Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms [J]. Ann Surg, 2003, 238(3):423-431.
29. Yang YM, Liu TH, Chen YJ, Jiang WJ, Qian JM, Lu X, Gao J, Wu SF, Sang XT, Chen J. Chromosome 1q loss of heterozygosity frequently occurs in sporadic insulinomas and is associated with tumor malignancy [J]. Int J Cancer, 2005, 117(2):234-240.
30. Jiang WJ, Liu TH, Chen J, Gao J, Wu SF, Chen YJ. Frequent loss of heterozygosity at MEN-1 gene and chromosome 22q in insulinomas and its significance [J]. Zhonghua yi xue za zhi, 2004, 84(20): 1705-1709.
31． 萨姆布鲁克J,拉塞尔D．W．著,黄培堂等译．分子克隆实验指南(第三版)[M]．北京：科学出版社,2002．
32. Eads CA, Laird PW. Combined bisulfite restriction analysis (COBRA) [J]. Methods Mol Biol, 2002, 200:71-85.
33. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands [J]. Proc Natl Acad Sci U S A, 1996, 93(18):9821-9826.
34. Deng DJ,Zhou J,Zhu BD,Ji JF,Harper JC,Powell SM. Silencing-specific methylation and single nucleotide polymorphism of hMLH1 promoter in gastric carcinomas [J]. World J Gastroenterol, 2003, 9(1):26-29.
35. Wang RY, Gehrke CW, Ehrlich M. Comparison of bisulfite modification of 5-methyldeoxycytidine and deoxycytidine residues [J]. Nucleic Acids Res, 1980, 8(20):4777-4790.
36. Deng G, Chen A, Hong J, Chae HS, Kim YS. Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression [J]. Cancer Res, 1999, 59(9):2029-2033.
37. Deng D,Deng G,Smith MF,Zhou J,Xin H,Powell SM,Lu Y. Simultaneous detection of CpG methylation and single nucleotide polymorphism by denaturing high performance liquid chromatography [J]. Nucleic Acids Res,2002,30(3):E13.
38. Chen YJ,Vortmeyer A.Zhuang Z,Huang S,Jensen RT. Loss of heterozygosity of chromosome 1q in gastrinomas: occurrence and prognostic significance [J]. Cancer Res, 2003, 63(4):817-823.
39. Xicola RM,LIor X,Pons E,Castells A,AIenda C,Pinol V,Andreu M, Castellvi-Bel S,Paya A,Jover R et al. Performance of different microsatellite marker panels for detection of mismatch repair-deficient colorectal tumors [J]. J Natl Cancer Inst, 2007, 99(3):244-252.
40. Zauber NP, Sabbath-Solitare M, Marotta SP, McMahon L, Bishop DT. Comparison of allelic ratios from paired blood and paraffin-embedded normal tissue for use in a polymerase chain reaction to assess loss of heterozygosity [J]. Mol Diagn, 1999, 4(1):29-35.
41. Holinski-Feder E, Muller-Koch Y, Friedl W, Moeslein G, Keller G, Plaschke J, Ballhausen W, Gross M, Baldwin-Jedele K, Jungck M et al. DHPLC mutation analysis of the hereditary nonpolyposis colon cancer (HNPCC) genes hMLH1 and hMSH2 [J]. J Biochem Biophys Methods, 2001, 47(1-2):21-32.
42. Kurzawski G,Safranow K,Suchy J,Chlubek D,Scott RJ,Lubinski J. Mutation analysis of MLH1 and MSH2 genes performed by denaturing high-performance liquid chromatography[J].J Biochem Biophys Methods,2002,51(1):89-100.
43.Bahrami AR,Dickman MJ,Matin MM,Ashby JR,Brown PE,Conroy M J,Fowler GJ,Rose JP,Sheikh QI,Yeung AT et al.Use of fluorescent DNA-intercalating dyes in the analysis of DNA via ion-pair reversed-phase denaturing high-performance liquid chromatography[J].Anal Biochem,2002,309(2):248-252.
44.蒋卫君,刘彤华,陈杰,等.胰岛素瘤频发MEN-1抑癌基因及22q的杂合缺失及其意义[J].中华医学杂志,2004,84:1705-1709.
45.吴海燕,赵大春,梅玫,陈杰,卢欣,杜顺达,周春宇,桑新亭,陈原稼.Ki-67在胰岛素瘤中的表达及其意义[J].胃肠病学,2008,13(4):209-212.
46.Gibril F,Jensen RT.Clinical Gastroenterology and Hepatology[M].London:ELSEVIER,2005:811-822.
47.Gumbs AA,Moore PS,Falconi M,Bassi C,Beghelli S,Modlin I,Scarpa A.Review of the clinical,histological,and molecular aspects of pancreatic endocrine neoplasms[J].J Surg Oncol,2002,81(1):45-53.
48.De Schutter H,Spaepen M,Mc Bride WH,Nuyts S.The clinical relevance of microsatellite alterations in head and neck squamous cell carcinoma:a critical review[J].Eur J Hum Genet,2007,15(7):734-741.
49.Kaz A,Kim YH,Dzieciatkowski S,Lynch H,Watson P,Kay Washington M,Lin L,Grady WM.Evidence for the role of aberrant DNA methylation in the pathogenesis of Lynch syndrome adenomas[J].Int J Cancer,2007,120(9):1922-1929.
50.Velasco A,Corvalan A,Wistuba,Ⅱ,Riquelme E,Chuaqui R,Majerson A,Leach FS.Mismatch repair expression in testicular cancer predicts recurrence and survival[J].Int J Cancer,2008,122(8):1774-1777.
51.Arnold CN,Sosnowski A,Schmitt-Graff A,Arnold R,Blum HE.Analysis of molecular pathways in sporadic neuroendocrine tumors of the gastro-entero-pancreatic system[J].Int J Cancer,2007,120(10):2157-2164.
52.Capel E,Flejou JF,Hamelin R.Assessment of MLH1 promoter methylation in relation to gene expression requires specific analysis[J].Oncogene,2007,26(54):7596-7600.
53.Ollikainen M,Hannelius U,Lindgren CM,Abdel-Rahman WM,Kere J, Peltomaki P. Mechanisms of inactivation of MLH1 in hereditary nonpolyposis colorectal carcinoma: a novel approach [J]. Oncogene,2007,26(31):4541-4549.
54. Park SJ, Rashid A, Lee JH, Kim SG, Hamilton SR, Wu TT. Frequent CpG island methylation in serrated adenomas of the colorectum [J]. Am J Pathol, 2003, 162(3):815-822.
55. Kim GP, Colangelo LH, Wieand HS, Paik S, Kirsch IR, Wolmark N, Allegra CJ. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study [J]. J Clin Oncol, 2007, 25(7):767-772.
56. Chen J, Sadowski I. Identification of the mismatch repair genes PMS2 and MLH1 as p53 target genes by using serial analysis of binding elements [J]. Proc Natl Acad Sci U S A, 2005, 102(13):4813-4818.
57. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis [ J ]. J Clin Oncol, 2005, 23(3):609-618.
1.刘丹.胰岛素瘤和正常胰腺蛋白质组差异比较的初步研究[D].北京:北京协和医学院,2005:
2.Ho CL,Liem RK.Intermediate filaments in the nervous system:implications in cancer[J].Cancer Metastasis Rev,1996,15(4):483-497.
3.Barry DM,Millecamps S,Julien JP,Garcia ML.New movements in neurofilament transport,turnover and disease[J].Exp Cell Res,2007,313(10):2110-2120.
4.Yuan A,Rao MV,Sasaki T,Chen Y,Kumar A,Veeranna,Liem RK,Eyer J,Peterson AC,Julien JP et al.Alpha-internexin is structurally and functionally associated with the neurofilament triplet proteins in the mature CNS[J].J Neurosci,2006,26(39):10006-10019.
5.Rauch U,Klotz M,Maas-Omlor S,Wink E,Hansgen A,Hagl C,Holland-Cunz S,Schafer KH.Expression of intermediate filament proteins and neuronal markers in the human fetal gut[J].J Histochem Cytochem,2006,54(1):39-46.
6.Behrends U,Jandl T,Golbeck A,Lechner B,Muller-Weihrich S,Schmid I,Till H,Berthold F,Voltz R,Mautner JM.Novel products of the HUD,HUC,NNP-1and alpha-internexin genes identified by autologous antibody screening of a pediatric neuroblastoma library[J].Int J Cancer,2002,100(6):669-677.
7.Chan SO,Runko E,Anyane-Yeboa K,Ko L,Chiu FC.Calcium ionophore-induced degradation of neurofilament and cell death in MSN neuroblastoma cells[J].Neurochem Res,1998,23(3):393-400.
8.Armstrong RA,Cairns NJ.Spatial patterns of the pathological changes in neuronal intermediate filament inclusion disease(NIFID):an alpha-internexin immunohistochemical study[J].J Neural Transm,2007,114(4):451-456.
9.Foley J,Witte D,Chiu FC,Parysek LM.Expression of the neural intermediate filament proteins peripherin and eurofilament-66 /alpha-internexin in neuroblastoma[J].Lab Invest,1994,71(2):193-199.
10.Willoughby V,Sonawala A,Werlang-Perurena A,Donner LR.A comparative immunohistochemical analysis of small round cell tumors of childhood:utility of peripherin and alpha-internexin as markers for neuroblastomas[J].Appl Immunohistochem Mol Morphol,2008,16(4):344-348.
11.Donner LR,Teshima I.Peripheral medulloepithelioma:an immunohistochemical,ultrastructural,and cytogenetic study of a rare,chemotherapy-sensitive,pediatric tumor[J].Am J Pathol,2003,27(7):1008-1012
12.Ikeda H,Yoshimoto T.Immunohistochemical study of anaplastic meningioma with special reference to the phenotypic change of intermediate filament protein[J].Ann Diagn Pathol,2003,7(4):214-222.
13.Kaya B,Mena H,Miettinen M,Rushing EJ.Alpha-internexin expression in medulloblastomas and atypical teratoid-rhabdoid tumors[J].Clin Neuropathol,2003,22(5):215-221.
14.萨姆布鲁克J,拉塞尔D.W.著,黄培堂等译.分子克隆实验指南(第三版)[M].北京:科学出版社,2002.
15.鄂征.组织培养技术及其在医学研究中的应用[M].北京:中国协和医科大学出版社,1999.
16.Halfdanarson TR,Rubin J,Farnell MB,Grant CS,Petersen GM.Pancreatic endocrine neoplasms:epidemiology and prognosis of pancreatic endocrine tumors[J].Endocr Relat Cancer,2008,15(2):409-427.
17.House MG,Schulick RD.Endocrine tumors of the pancreas[J].Curr Opin Oncol,2006,18(1):23-29.
18.Jonkers YM,Ramaekers FC,Speel EJ.Molecular alterations during insulinoma tumorigenesis[J].Biochim Biophys Acta,2007,1775(2):313-332.
19.Oberg K,Eriksson B.Endocrine tumours of the pancreas[J].Best Pract Res Clin Gastroenterol,2005,19(5):753-781.
20.Jensen RT.Carcinoid and pancreatic endocrine tumors:recent advances in molecular pathogenesis,localization,and treatment[J].Curr Opin Oncol,2000,12(4):368-377.
21.Jensen R.Pancreatic endocrine tumors:recent advances[J].Ann Oncol,1999,10(Suppl 4):170-176.
22.Corleto VD,Delle Fave G,Jensen RT.Molecular insights into gastrointestinal neuroendocrine tumours:importance and recent advances [J].Dig Liver Dis,2002,34(9):668-680.
23. Cupisti K,Hoppner W,Dotzenrath C,Simon D,Berndt I, Roher HD, Goretzki PE. Lack of MEN1 gene mutations in 27 sporadic insulinomas [J]. Eur J Clin Invest, 2000, 30(4):325-329.
24. Jonkers YM,CIaessen SM,Perren A,Schmid S,Komminoth P, Verhofstad AA,Hofland LJ,de Krijger RR,SIootweg PJ, Ramaekers FC et al. Chromosomal instability predicts metastatic disease in patients with insulinomas [J]. Endocr Relat Cancer, 2005, 12(2):435-447.
25. Zhuang Z, Vortmeyer AO, Pack S, Huang S, Pham TA, Wang C, Park WS, Agarwal SK, Debelenko LV, Kester M et al. Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas [J]. Cancer Res, 1997, 57(21):4682-4686.
26. Zikusoka MN, Kidd M, Eick G, Latich I, Modlin IM. The molecular genetics of gastroenteropancreatic neuroendocrine tumors [J]. Cancer, 2005, 104(11):2292-2309.
27. Gumbs AA, Moore PS, Falconi M, Bassi C, Beghelli S, Modlin I, Scarpa A. Review of the clinical, histological, and molecular aspects of pancreatic endocrine neoplasms [J]. J Surg Oncol, 2002, 81(1):45-53
28. Mansour JC, Chen H. Pancreatic endocrine tumors [J]. J Surg Res, 2004, 120(1):139-161.
29. Ducray F,Criniere E,ldbaih A,Mokhtari K,Marie Y.Paris S,Navarro S, Laigle-Donadey F,Dehais C,Thillet J et al. alpha-Internexin expression identifies 1p19q codeleted gliomas [J]. Neurology, 2009, 72(2):156-161.
30. Pape UF,Bemdt U,Muller-Nordhorn J,Bohmig M,Roll S,Koch M, Willich SN,Wiedenmann B. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours[J]. Endocr Relat Cancer, 2008, 15(4): 1083-1097.
31. Lepage C, Rachet B, Coleman MP. Survival from malignant digestive endocrine tumors in England and Wales: a population-based study [J]. Gastroenterology, 2007, 132(3):899-904.
32. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? [J]. Nat Rev Cancer, 2006, 6(2):107-116.
33. Santos-Reboucas CB, Pimentel MM: Implication of abnormal epigenetic patterns for human diseases [J]. Eur J Hum Genet, 2007, 15(1): 10-17.
34. Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells[J].Nat Rev Cancer,2005,5(3):223-231.
35.沈翊琲.染色体与表观遗传调控[M],北京:高等教育出版社:2006,35-7536.Fraga M F,Ballestar E,Villar-Garea A,Boix-Chornet M,Espada J,Schotta G,Bonaldi T,Haydon C,Ropero S,Petrie K et al.Loss of acetylation at Lys16and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer[J].Nat Genet,2005,37(4):391-400.
1.Oberg K,Eriksson B.Endocrine tumours of the pancreas[J].Best Pract Res Clin Gastroenterol,2005,19(5):753-781.
2.Jonkers YM,Ramaekers FC,Speel EJ.Molecular alterations during insulinoma tumorigenesis[J].Biochim Biophys Acta,2007,1775(2):313-332.
3.陈元方等.胃肠肽类激素基础与临床[M].北京:北京医科大学中国协和医科大学联合出版社,1997:665.
4.陈原稼,梅玫.胰腺内分泌肿瘤临床、分子生物学和遗传学预后指标[J].胰腺病学,2004,4:182-186.
5.Jensen R.Pancreatic endocrine tumors:recent advances[J].Ann Oncol,1999,10(Suppl 4):170-176.
6.Perren A,Anlauf M,Henopp T,Rudolph T,Schmitt A,Raffel A,Gimm O,Weihe E,Knoefel WT,Dralle H et al.Multiple endocrine neoplasia type 1(MEN1):loss of one MEN1 allele in tumors and monohormonal endocrine cell clusters but not in islet hyperplasia of the pancreas[J].J Clin Endocrinol Metab,2007,92(3):1118-1128.
7.Zhao Y,Wang X,Yang B,Xiao Y,Cai L,Zhong S,Zhu Y.Pancreatic insulinomas:experience in 220 patients[J].Zhonghua wai ke za zhi,2000,38(1):10-13.
8.张太平,赵玉沛,郐占波等:胰岛素瘤误诊原因探讨和处理对策(附71例报告).胰腺病学,2002,2:31-33.
9.Halfdanarson TR,Rubin J,Farnell MB,Grant CS,Petersen GM.Pancreatic endocrine neoplasms:epidemiology and prognosis of pancreatic endocrine tumors[J].Endocr Relat Cancer,2008,15(2):409-427.
10.Berger AC,Gibril F,Venzon DJ,Doppman J L,Norton JA,Bartlett DL,Libutti SK,Jensen RT,Alexander HR,Prognostic value of initial fasting serum gastnn levels in patients with Zollinger-Ellison syndrome[J].J Clin Oncol,2001,19(12):3051-3057.
11.Yu F,Venzon DJ,Serrano J,Goebel SU,Doppman JL,Gibril F,Jensen RT.Prospective study of the clinical course,prognostic factors,causes of death,and survival in patients with long-standing Zollinger-Ellison syndrome[J].J Clin Oncol,1999,17(2):615-630.
12. Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B: Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution [J]. Clin Cancer Res, 2008,14(23):7798-7803.
13. La Rosa S, Klersy C, Uccella S, Dainese L, Albarello L, Sonzogni A, Doglioni C, Capella C, Solcia E. Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors [J]. Hum Pathol, 2009, 40(1):30-40.
14. Bettini R, Boninsegna L, Mantovani W, Capelli P, Bassi C, Pederzoli P, Delle Fave GF, Panzuto F, Scarpa A, Falconi M. Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours[J]. Ann Oncol, 2008, 19(5):903-908.
15. Diaz-Rubio JL, Duarte-Rojo A, Saqui-Salces M, Gamboa-Dominguez A, Robles-Diaz G. Cellular proliferative fraction measured with topoisomerase Ilalpha predicts malignancy in endocrine pancreatic tumors [J]. Arch Pathol Lab Med, 2004, 128(4):426-429.
16. You DD, Lee HG, Paik KY, Heo JS, Choi SH, Choi DW. The outcomes after surgical resection in pancreatic endocrine tumors: An institutional experience [J]. Eur J Surg Oncol, 2009.
17. Chung JC, Choi DW, Jo SH, Heo JS, Choi SH, Kim YI. Malignant nonfunctioning endocrine tumors of the pancreas: predictive factors for survival after surgical treatment [J]. World J Surg, 2007, 31 (3):579-585.
18. Hochwald SN, Zee S, Conlon KC, Colleoni R, Louie O, Brennan MF, Klimstra DS. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups [J]. J Clin Oncol, 2002, 20(11 ):2633-2642.
19. Marion-Audibert AM, Barel C, Gouysse G, Dumortier J, Pilleul F, Pourreyron C, Hervieu V, Poncet G, Lombard-Bohas C, Chayvialle JA et al. Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors [J]. Gastroenterology, 2003, 125(4): 1094-1104.
20. Takahashi Y, Akishima-Fukasawa Y, Kobayashi N, Sano T, Kosuge T, Nimura Y, Kanai Y, Hiraoka N. Prognostic value of tumor architecture, tumor-associated vascular characteristics, and expression of angiogenic molecules in pancreatic endocrine tumors [J]. Clin Cancer Res, 2007, 13(1):187-196.
21. Heitz PL) KP, Perren A, et al. Tumours of the endocrine pancreas [M]. Lyon: IARC Press; 2004.
22. Schmitt AM, Anlauf M, Rousson V, Schmid S, Kofler A, Riniker F, Bauersfeld J, Barghorn A, Probst-Hensch NM, Moch H et al. WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors [J]. Am J Surg Pathol, 2007, 31(11):1677-1682.
23. Jensen RT. Carcinoid and pancreatic endocrine tumors: recent advances in molecular pathogenesis, localization, and treatment [J]. Curr Opin Oncol, 2000, 12(4):368-377.
24. Serrano J, Goebel SU, Peghini PL, Lubensky IA, Gibril F, Jensen RT. Alterations in the p16INK4a/CDKN2A tumor suppressor gene in gastrinomas [J]. J Clin Endocrinol Metab, 2000, 85(11):4146-4156.
25. Corleto VD, Delle Fave G, Jensen RT. Molecular insights into gastrointestinal neuroendocrine tumours: importance and recent advances [J]. Dig Liver Dis, 2002, 34(9):668-680.
26. House MG, Schulick RD. Endocrine tumors of the pancreas [J]. Curr Opin Oncol, 2006, 18(1):23-29.
27. Zhuang Z, Vortmeyer AO, Pack S, Huang S, Pham TA, Wang C, Park WS, Agarwal SK, Debelenko LV, Kester M et al. Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas [J]. Cancer Res, 1997, 57(21):4682-4686.
28. Peghini PL, Iwamoto M, Raffeld M, Chen YJ, Goebel SU, Serrano J, Jensen RT. Overexpression of epidermal growth factor and hepatocyte growth factor receptors in a proportion of gastrinomas correlates with aggressive growth and lower curability [J]. Clin Cancer Res, 2002, 8(7):2273-2285.
29. Goebel SU, Iwamoto M, Raffeld M, Gibril F, Hou W, Serrano J, Jensen RT. Her-2/neu expression and gene amplification in gastrinomas: correlations with tumor biology, growth, and aggressiveness [J]. Cancer Res. 2002, 62(13):3702-3710.
30. Furukawa M, Raffeld M, Mateo C, Sakamoto A, Moody TW, Ito T, Venzon DJ, Serrano J, Jensen RT. Increased expression of insulin-like growth factor I and/or its receptor in gastrinomas is associated with low curability, increased growth, and development of metastases [J]. Clin Cancer Res, 2005, 11(9):3233-3242.
31. Hansel DE, Rahman A, Hermans J, de Krijger RR, Ashfaq R, Yeo CJ, Cameron JL, Maitra A. Liver metastases arising from well-differentiated pancreatic endocrine neoplasms demonstrate increased VEGF-C expression [J]. Mod Pathol, 2003, 16(7):652-659.
32. Deshpande V, Fernandez-del Castillo C, Muzikansky A, Deshpande A, Zukerberg L, Warshaw AL, Lauwers GY. Cytokeratin 19 is a powerful predictor of survival in pancreatic endocrine tumors [J]. Am J Surg Pathol, 2004, 28(9): 1145-1153.
33. La Rosa S, Rigoli E, Uccella S, Novario R, Capella C. Prognostic and biological significance of cytokeratin 19 in pancreatic endocrine tumours [J]. Histopathology, 2007, 50(5):597-606.
34. Grabowski P, Griss S, Arnold CN, Horsch D, Goke R, Arnold R, Heine B, Stein H, Zeitz M, Scherubl H. Nuclear survivin is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumor disease [J]. Neuroendocrinology, 2005, 81(1): 1-9.
35. Dalai I, Missiaglia E, Barbi S, Butturini G, Doglioni C, Falconi M, Scarpa A. Low expression of ARHl is associated with shorter progression-free survival in pancreatic endocrine tumors [J]. Neoplasia, 2007, 9(3):181-183.
36. Heitz PU, Kasper M, Kloppel G, Polak JM, Vaitukaitis JL. Glycoprotein-hormone alpha-chain production by pancreatic endocrine tumors: a specific marker for malignancy. Immunocytochemical analysis of tumors of 155 patients [J]. Cancer, 1983, 51 (2):277-282.
37. Graeme-Cook F, Bell DA, Flotte TJ, Preffer F, Pastel-Levy C, Nardi G, Compton C. Aneuploidy in pancreatic insulinomas does not predict malignancy [J]. Cancer, 1990, 66(11):2365-2368.
38. AN A, Serra S, Asa SL, Chetty R. The predictive value of CK19 and CD99 in pancreatic endocrine tumors [J]. Am J Surg Pathol, 2006, 30(12):1588-1594.
39. Rahman A, Maitra A, Ashfaq R, Yeo CJ, Cameron JL, Hansel DE. Loss of p27 nuclear expression in a prognostically favorable subset of well-differentiated pancreatic endocrine neoplasms[J]. Am J Clin Pathol, 2003, 120(5):685-690.
40. Ohike N, Morohoshi T. Immunohistochemical analysis of cyclooxygenase (COX)-2 expression in pancreatic endocrine tumors:association with tumor progression and proliferation[J].Pathol Int,2001,51(10):770-777.
41.Deschamps L,Handra-Luca A,O'Toole D,Sauvanet A,Ruszniewski P,Belghiti J,Bedossa P,Couvelard A.CD10 expression in pancreatic endocrine tumors:correlation with prognostic factors and survival[J].Hum Pathol,2006,37(7):802-808.
42.Imam H,Eriksson B,Oberg K.Expression of CD44 variant isoforms and association to the benign form of endocrine pancreatic tumours[J].Ann Oncol,2000,11(3):295-300.
43.Guo SS,Wu AY,Sawicki MP.Deletion of chromosome 1,but not mutation of MEN-1,predicts prognosis in sporadic pancreatic endocrine tumors[J].World J Surg,2002,26(7):843-847.
44.Chen Y J,Vortmeyer A,Zhuang Z,Huang S,Jensen RT.Loss of heterozygosity of chromosome 1q in gastrinomas:occurrence and prognostic significance[J].Cancer Res,2003,63(4):817-823.
45.Yang YM,Liu TH,Chen Y J,Jiang W J,Qian JM,Lu X,Gao J,Wu SF,Sang XT,Chen J.Chromosome 1q loss of heterozygosity frequently occurs in sporadic insulinomas and is associated with tumor malignancy[J].Int J Cancer,2005,117(2):234-240.
46.蒋卫君,刘彤华,陈杰等.胰岛素瘤频发MEN-1抑癌基因及22q的杂合缺失及其意义[J].中华医学杂志,2004,84:1705-1709.
47.Pizzi S,D'Adda T,Azzoni C,Rindi G,Grigolato P,Pasquali C,Corleto VD,Delle Fave G,Bordi C.Malignancy-associated allelic losses on the X-chromosome in foregut but not in midgut endocrine tumours[J].J Pathol,2002,196(4):401-407.
48.Missiaglia E,Moore PS,Williamson J,Lemoine NR,Falconi M,Zamboni G,Scarpa A.Sex chromosome anomalies in pancreatic endocrine tumors[J].Int J Cancer,2002,98(4):532-538.
49.Chen Y J,Vortmeyer A,Zhuang Z,Gibril F,Jensen RT.X-chromosome loss of heterozygosity frequently occurs in gastrinomas and is correlated with aggressive tumor growth[J].Cancer,2004,100(7):1379-1387.
50.Guo SS,Arora C,Shimoide AT,Sawicki MP.Frequent deletion of chromosome 3 in malignant sporadic pancreatic endocrine tumors[J].Mol Cell Endocrinol,2002,190(1-2):109-114.
51. Barghorn A, Komminoth P, Bachmann D, Rutimann K, Saremaslani P, Muletta-Feurer S, Perren A, Roth J, Heitz PU, Speel EJ. Deletion at 3p25.3-p23 is frequently encountered in endocrine pancreatic tumours and is associated with metastatic progression [J]. J Pathol, 2001, 194(4):451-458.
52. Hessman O, Lindberg D, Einarsson A, Lillhager P, Carling T, Grimelius L, Eriksson B, Akerstrom G, Westin G, Skogseid B. Genetic alterations on 3p, 11q13, and 18q in nonfamilial and MEN 1-associated pancreatic endocrine tumors [J]. Genes chromosomes cancer, 1999, 26(3):258-264.
53. Barghorn A, Speel EJ, Farspour B, Saremaslani P, Schmid S, Perren A, Roth J, Heitz PU, Komminoth P. Putative tumor suppressor loci at 6q22 and 6q23-q24 are involved in the malignant progression of sporadic endocrine pancreatic tumors [J]. Am J Pathol, 2001, 158(6):1903-1911.
54. Speel EJ, Scheidweiler AF, Zhao J, Matter C, Saremaslani P, Roth J, Heitz PU, Komminoth P. Genetic evidence for early divergence of small functioning and nonfunctioning endocrine pancreatic tumors: gain of 9Q34 is an early event in insulinomas [J]. Cancer Res, 2001, 61(13):5186-5192.
55. Beghelli S, Pelosi G, Zamboni G, Falconi M, lacono C, Bordi C, Scarpa A. Pancreatic endocrine tumours: evidence for a tumour suppressor pathogenesis and for a tumour suppressor gene on chromosome 17p [J]. J Pathol, 1998, 186(1):41-50.
56. House MG, Herman JG, Guo MZ, Hooker CM, Schulick RD, Lillemoe KD, Cameron JL, Hruban RH, Maitra A, Yeo CJ. Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms [J]. Ann Surg, 2003, 238(3):423-431
57. House MG, Herman JG, Guo MZ, Hooker CM, Schulick RD, Cameron JL, Hruban RH, Maitra A, Yeo CJ. Prognostic value of hMLH1 methylation and microsatellite instability in pancreatic endocrine neoplasms [J]. Surgery, 2003, 134(6):902-908.
58. Liu L, Broaddus RR, Yao JC, Xie S, White JA, Wu TT, Hamilton SR, Rashid A. Epigenetic alterations in neuroendocrine tumors: methylation of RAS-association domain family 1, isoform A and p16 genes are associated with metastasis [J]. Mod Pathol, 2005, 18(12):1632-1640.